TreatmentTrends

July 2013

TreatmentTrends®: MRSA and Serious Gram-Positive Infections (US) 2013

Introduction:

This report provides insight into the management of patients with serious Gram-positive (GP) infections in the hospital setting and analyzes the hospital antibiotic prescribing practices for the treatment of key infections due to emerging and clinically-important Gram-positive pathogens, such as CA-MRSA, HA-MRSA, VISA, VRSA, and VRE.
TreatmentTrends® is a syndicated report series that provides longitudinal information on market dynamics, including insight into practice pat-terns, attitudes and perceptions, unmet needs, and projected use of antibiotics in the hospital setting. These studies also explore the perceived advantages and disadvantages of currently available therapies and therapies in development.

Questions Answered in This Report:

  *   Understand the patient populations treated for MRSA and serious GP infections in the hospital with respect to age, gender, treatment hospital demographics, risk factors, comorbidities, and treatment outcomes, including re-admissions


  *   Evaluate treatment of serious infections due to emerging and clinically-important pathogens (including drug-resistant strains), identify which pathogens are of concern to physicians, and which pose new treatment challenges and drug development opportunities


  *   Understand how physicians make treatment choices for MRSA and GP infections, including choosing empiric treatment for suspected MRSA infections and preferred discharge therapies


  *   Understand the treatment of patients with a range of MRSA infections (e.g., cSSSIs, bloodstream infections, nosocomial pneumonia, IAIs, and bone and joint infections)


  *   Understand physicians' preference for therapies and analyze factors and drug attributes that influence and alter their current and future prescribing patterns


  *   Understand ID physicians’ receptivity to novel and developing MRSA and GP therapies

Scope:

Sample Frame & Methodology:

- 100 hospital-based infectious diseases (ID) specialists complete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback

- Respondents have at least 50% of their practice that is hospital, patient-based

- Minimum of 2 years of post-residency experience and a maximum of 30 years in practice

Deliverables:

- Final report in PowerPoint

- Complete set of frequency tables and standard cross tabulations

- Clients committing to the project prior to fielding will be invited to comment on the survey tool and may include up to three proprietary questions in the physician survey

Product Coverage:

VANCOMYCIN, DAPTOMYCIN, LINEZOLID, TELAVANCIN, TEFLARO, TIGECYCLINE, TMP-SMZ, CLINDAMYCIN, QUINUPRISTIN/DALFOPRISTIN AND OTHERS

VARIOUS PHASE II AND III PRODUCTS IN DEVELOPMENT

Related Products:

- TreatmentTrends®: MRSA and Serious Gram-Positive Infections (EU)

- TreatmentTrends®: Gram-Negative Infections (US)

- TreatmentTrends®: Gram-Negative Infections (EU)

- TreatmentTrends®: Pneumonia (US)

- Special Reports: Hospital Discharge and Outpatient Trends

- AMR's Hospital Antibiotic Market Guide

- Pharmacor®: MRSA

- Physician & Payer Forum®: OPAT for Skin Infections and Osteomyelitis

- DecisionBase®: HAP/VAP

Search Published Reports


Decision Resources Group brands include: